Austria: Schoenherr advises listed AddLife on its acquisition of DACH Medical Group
Schoenherr, together with Advokatfirman Delphi, advised AddLife, a Swedish Medtech company listed on the Nasdaq Nordic Exchange, Stockholm, on the acquisition of all shares in the DACH Medical Group Holding AG. The transaction agreement was signed on 1 October 2020.
AddLife is an independent operator in the Life Sciences industry that offers high-quality products, services and consulting in both the private and public sectors, mainly in the Nordic region and throughout the rest of Europe. The Group has annual sales of approximately SEK 4.1 billion (approx. EUR 400 million).
DACH Medical Group Holding AG is the parent company of DACH Medical Group with net sales of approximately EUR 14 million, with operations in the advanced surgery product area with headquarters in Switzerland, Austria and Germany. It markets and sells both own brands and products from leading suppliers in advanced surgery such as laparoscopy and endoscopy, urology, thoracic medicine and gynaecology.
Schoenherr advised AddLife on all legal aspects of the transaction, including the acquisition agreement and due diligence. The Schoenherr team was led by Christian Herbst (partner) and Maximilian Lang (counsel) and further consisted of Maximilian Nutz (associate) and Teresa Waidmann (attorney at law).
The Sellers of DACH Medical Group were represented by SCWP Schindhelm.